Data were pooled from several studies on nicotinic acid (NiAc) intervention of fatty acid turnover in normal Sprague-Dawley and obese Zucker rats in order to perform a joint PKPD of data from more than 100 normal Sprague-Dawley and obese Zucker rats, exposed to several administration routes and rates. To describe the difference in pharmacodynamic parameters between obese and normal rats, we modified a previously published nonlinear mixed effects model describing tolerance and oscillatory rebound effects of NiAc on nonesterified fatty acids plasma concentrations. An important conclusion is that planning of experiments and dose scheduling cannot rely on pilot studies on normal animals alone. The obese rats have a less-pronounced concentration...
Inclusion of stochastic differential equations in mixed effects models provides means to quantify an...
BACKGROUND: Activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPARdelta cause...
Background: Non-alcoholic steatohepatitis (NASH), a subtype of non-alcoholic fatty liver disease (NA...
Data were pooled from several studies on nicotinic acid (NiAc) intervention of fatty acid turnover i...
ABSTRACTData were pooled from several studies on nicotinic acid (NiAc) intervention of fatty acid tu...
Data were pooled from several studies on nicotinic acid (NiAc) intervention of fatty acid turnover i...
The development of rebound and tolerance is an important consideration when optimizing medical thera...
The objective of this investigation was to use a pharmacokinetic (PK)/pharmacodynamic (PD) approach ...
Nicotinic acid (NiAc) is a potent inhibitor of adipose tissue lipolysis. Acute administration result...
Type 2 diabetes is a devastating disease affecting hundreds of millions worldwide. Lipid accumulatio...
Nicotinic acid (NiAc) is a potent inhibitor of adipose tissue lipolysis. Acute administration result...
The objective of this investigation was to use a pharmacokinetic (PK)/pharmacodynamic (PD) approach ...
This study presents a dose–response-time (DRT) analysis based on a large preclinical biomarker datas...
Objectives: To demonstrate the utility of a dose-response-time (DRT) model using a large preclinical...
\ua9 2015 Elsevier B.V. All rights reserved. This study presents a dose-response-time (DRT) analysis...
Inclusion of stochastic differential equations in mixed effects models provides means to quantify an...
BACKGROUND: Activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPARdelta cause...
Background: Non-alcoholic steatohepatitis (NASH), a subtype of non-alcoholic fatty liver disease (NA...
Data were pooled from several studies on nicotinic acid (NiAc) intervention of fatty acid turnover i...
ABSTRACTData were pooled from several studies on nicotinic acid (NiAc) intervention of fatty acid tu...
Data were pooled from several studies on nicotinic acid (NiAc) intervention of fatty acid turnover i...
The development of rebound and tolerance is an important consideration when optimizing medical thera...
The objective of this investigation was to use a pharmacokinetic (PK)/pharmacodynamic (PD) approach ...
Nicotinic acid (NiAc) is a potent inhibitor of adipose tissue lipolysis. Acute administration result...
Type 2 diabetes is a devastating disease affecting hundreds of millions worldwide. Lipid accumulatio...
Nicotinic acid (NiAc) is a potent inhibitor of adipose tissue lipolysis. Acute administration result...
The objective of this investigation was to use a pharmacokinetic (PK)/pharmacodynamic (PD) approach ...
This study presents a dose–response-time (DRT) analysis based on a large preclinical biomarker datas...
Objectives: To demonstrate the utility of a dose-response-time (DRT) model using a large preclinical...
\ua9 2015 Elsevier B.V. All rights reserved. This study presents a dose-response-time (DRT) analysis...
Inclusion of stochastic differential equations in mixed effects models provides means to quantify an...
BACKGROUND: Activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPARdelta cause...
Background: Non-alcoholic steatohepatitis (NASH), a subtype of non-alcoholic fatty liver disease (NA...